Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Safety and Efficacy Evaluation of BLI801 Laxative in Constipated Adults

This study has been completed.
Information provided by (Responsible Party):
Braintree Laboratories Identifier:
First received: September 14, 2012
Last updated: July 14, 2014
Last verified: July 2014
A pilot study to evaluate the safety and efficacy of multiple BLI801 doses in constipated adults.

Condition Intervention Phase
Drug: BLI801 laxative - low dose
Drug: BLI801 laxative - high dose
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Safety and Efficacy Evaluation of BLI801 Laxative in Constipated Adults

Resource links provided by NLM:

Further study details as provided by Braintree Laboratories:

Primary Outcome Measures:
  • Treatment Success [ Time Frame: 4 weeks ]
    percent of patients experiencing a response in 3 out of 4 weeks of treatment

Secondary Outcome Measures:
  • serum chemistry [ Time Frame: 4 weeks ]

Enrollment: 81
Study Start Date: August 2012
Study Completion Date: March 2013
Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BLI801 laxative - low dose
BLI801 laxative - oral solution
Drug: BLI801 laxative - low dose
BLI801 laxative - oral solution
Experimental: BLI801 laxative - high dose
BLI801 laxative - oral solution
Drug: BLI801 laxative - high dose
BLI801 laxative - oral solution
Other Name: BLI801


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Male or female subjects at least 18 years of age

Constipated, defined by ROME definition:

Otherwise in good health, as determined by physical exam and medical history

Exclusion Criteria:

Subjects with known or suspected ileus, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis, toxic megacolon

Subjects taking laxatives or prokinetic agents that refuse to discontinue these treatments

Subjects who are allergic to any BLI801 component

Subjects currently taking narcotic analgesics or other medications known to cause constipation

Subjects who, in the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures

Subjects who have participated in an investigational clinical, surgical, drug, or device study within the past 30 days

Subjects with an active history of drug or alcohol abuse

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01687985

United States, California
Anaheim Clinical Trials
Anaheim, California, United States, 92801
United States, Massachusetts
Commonwealth Clinical Studies
Brockton, Massachusetts, United States, 02302
United States, Tennessee
Chattanooga, Tennessee, United States, 37421
Memphis Gastroenterology
Germantown, Tennessee, United States, 38138
Sponsors and Collaborators
Braintree Laboratories
Study Director: John McGowan, MPH Braintree Laboratories, Inc.
  More Information

Responsible Party: Braintree Laboratories Identifier: NCT01687985     History of Changes
Other Study ID Numbers: BLI801-202
Study First Received: September 14, 2012
Last Updated: July 14, 2014

Additional relevant MeSH terms:
Signs and Symptoms, Digestive
Signs and Symptoms
Pharmaceutical Solutions
Gastrointestinal Agents processed this record on May 25, 2017